Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole brain radiotherapy + G-CSF to enhance immunotherapy in NSCLC brain metastases
ChiCTR2200063621Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Nov 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of filgrastim in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Intracranial progression-free survival. Started Nov 2021; status: recruiting.
02
Drugs
filgrastim
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2200063621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063621.